Targeted therapies and clinical trials in ovarian cancer (Q38165164)

30 August 2017

Targeted therapies and clinical trials in ovarian cancer (English)

1 reference

30 August 2017

1 reference

J Dancey

1

1 reference

30 August 2017

1 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

24 Suppl 10

1 reference

30 August 2017

x59-x63

1 reference

30 August 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Recent progress in the diagnosis and treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Ovarian clear cell adenocarcinoma: a continuing enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

PPM1D is a potential therapeutic target in ovarian clear cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Tiling path genomic profiling of grade 3 invasive ductal breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Trastuzumab in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Identification of novel therapeutic targets in microdissected clear cell ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Low-grade serous carcinoma: new concepts and emerging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Effective incorporation of biomarkers into phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

MEK and RAF inhibitors for BRAF-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT473

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT473

1 reference

30 August 2017

1 reference

PubMed ID

24265407